Harvard Bioscience Inc
HBIO- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001123494
No open-market purchases or sales by Harvard Bioscience Inc insiders were filed in the last 90 days; 37 institutions reported holding it in 13F filings for Q2 2026, worth $10.3M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Harvard Bioscience Inc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 100
- +10 vs. Q1 2024
- Shares held
- 31.8M
- −699.0K (−2.2%) vs. Q1 2024
- Total value
- $90.7M
- −$47.2M (−34.2%) vs. Q1 2024
- New holders
- 21
- 42 more added
- Sold out
- 11
- 25 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 37 | $10.3M |
| Q1 2026 | 37 | $7.73M |
| Q4 2025 | 64 | $11.7M |
| Q3 2025 | 61 | $7.29M |
| Q2 2025 | 69 | $8.39M |
| Q1 2025 | 92 | $14.5M |
| Q4 2024 | 96 | $65.5M |
| Q3 2024 | 95 | $84.2M |
| Q2 2024 | 100 | $90.7M |
| Q1 2024 | 90 | $137.8M |
| Q4 2023 | 93 | $176.4M |
| Q3 2023 | 94 | $141.6M |
| Q2 2023 | 100 | $178.2M |
| Q1 2023 | 66 | $127.2M |
| Q4 2022 | 68 | $83.3M |
| Q3 2022 | 79 | $74.0M |
| Q2 2022 | 91 | $106.8M |
| Q1 2022 | 98 | $187.3M |
| Q4 2021 | 103 | $211.4M |
| Q3 2021 | 99 | $191.7M |
| Q2 2021 | 99 | $232.3M |
| Q1 2021 | 87 | $144.2M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Harvard Bioscience Inc; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Archon Capital Management LLC | 0 | $0 | 0.00% | −260,858−100.0% | Sold out |
| Hillsdale Investment Management Inc. | 0 | $0 | 0.00% | −26,400−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −21,151−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −19,980−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −16,564−100.0% | Sold out |
| O'Shaughnessy Asset Management, LLC | 0 | $0 | 0.00% | −15,502−100.0% | Sold out |
| Voya Investment Management LLC | 0 | $0 | 0.00% | −14,506−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −13,233−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −2,337−100.0% | Sold out |
| Concord Wealth Partners | 0 | $0 | 0.00% | −2,250−100.0% | Sold out |
| Hantz Financial Services, Inc. | 0 | $0 | 0.00% | −2−100.0% | Sold out |